Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M‐positive NSCLC: A retrospective study

Zhou, Bin; Gong, Qiang; Li, Ben; Qie, Hai-Ling; Li, Wei; Jiang, Hai; Li, Hefei

doi:10.1111/jcpt.13591

Cited by 6 publications

(6 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In third-line treatments, the combination of osimetinib with anlotinib initially demonstrated encouraging clinical results, consistent with previous studies [ 42 , 43 ]. The mOS was 13.2 months, which was significantly higher than the survival observed in patients who received anlotinib alone, other TKIs therapy or chemotherapy after resistance to osimertinib.…”

Section: Discussionsupporting

confidence: 86%

Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer

Bai,

Zhou,

Liu

et al. 2024

Heliyon

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 86%

Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer

Bai,

Zhou,

Liu

et al. 2024

Heliyon

View full text Add to dashboard Cite

“…The mPFS was 15.5 months and mOS was 23.8 months. 26 In this study, the ORR and DCR of osimertinib-resistant NSCLC patients treated with osimertinib combined with anlotinib were 20.6% and 88.2%, respectively. In terms of safety, the retrospective analysis of the patients in this study showed that there were three cases of grade 3 adverse events (hypertension, vomiting, and proteinuria), which were gradually controlled after drug withdrawal or symptomatic treatment.…”

Section: Discussionmentioning

confidence: 58%

“…The results showed that after osimertinib combined with anlotinib, one patient achieved CR, meanwhlie ORR and DCR were 81.8% and 97.0%, respectively. The mPFS was 15.5 months and mOS was 23.8 months 26 …”

Section: Discussionmentioning

confidence: 94%

Efficacy and safety of osimertinib plus anlotinib in advanced non‐small‐cell lung cancer patients after drug resistance

Wang

Zhao²,

Chen

et al. 2023

Thoracic Cancer

View full text Add to dashboard Cite

Objective To retrospectively analyze the efficacy and safety of osimertinib combined with anlotinib in the treatment of advanced non‐small‐cell lung cancer (NSCLC) after drug resistance, and to explore the related factors affecting the efficacy. Methods The clinical data of 34 patients with advanced NSCLC who received osimertinib combined with anlotinib as three or more lines of treatment in the Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College from June 2019 to March 2022 were collected, and the therapeutic efficacy and safety were analyzed. Results A total of 34 advanced NSCLC patients met the inclusion criteria. The objective response rate was 20.6%, the disease response rate was 88.2%, the median overall survival was 19.0 months, and the median progression‐free survival was 6.0 months. The common adverse events were mainly grade 1–2, and only three cases (11.1%) of adverse events were grade 3, including hypertension, proteinuria, and vomiting. No grade 4 or above adverse events were observed. Multivariate Cox regression analysis showed that the Eastern Cooperative Oncology Group Performance Status score and bone metastasis were independent prognostic factors for osimertinib combined with anlotinib as three or more lines of treatment in advanced NSCLC. Conclusions Osimertinib combined with anlotinib as three or more lines of treatment in advanced NSCLC was effective and adverse events were tolerable.

show abstract

“…FGFR overexpression is mechanism of resistance to both EGFR-TKIs and cytotoxic chemotherapy, which is likely why the anlotinib benefit was consistent in patients whose tumors harbor EGFR mutations regardless of whether they were most recently treated with chemotherapy or an EGFR-TKI (26,27). This is also the basis for an ongoing study combining osimertinib and anlotinib for the first-line treatment of patient with advanced EGFR mutated NSCLC (28,29).…”

Section: Discussionmentioning

confidence: 89%

The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study

Zhao¹,

Wang²,

Zhang³

et al. 2022

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background: Anlotinib demonstrated improved overall survival (OS) and progression-free survival (PFS) compared with placebo as a third-line or subsequent therapy in patients with non-small cell lung cancer (NSCLC) in the ALTER0303 trial. The status of epidermal growth factor receptor (EGFR) mutation, different previous treatment may affect the efficacy of subsequent therapy, and we did this subgroup analysis to characterize the efficacy of anlotinib in patients with and without EGFR mutation.Methods: The ALTER0303 trial was a randomized, double-blind, phase 3 study of anlotinib in patients with NSCLC who failed at least 2 lines of treatment. In the study, 138 of 437 randomized patients were EGFR mutation positive. A Cox model was used to examine the influence of previous treatment on the efficacy of anlotinib according to EGFR mutation status.Results: For patients with EGFR mutation, the OS was 10.7 and 6.3 months (HR 0.59; 95% CI: 0.38-0.94, P=0.025) in the anlotinib and placebo group, respectively. The PFS was 5.6 and 0.8 months (HR 0.21; 95%

show abstract

Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M‐positive NSCLC: A retrospective study

Cited by 6 publications

References 29 publications

Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer

Genetic mutation profiling reveals biomarkers for targeted therapy efficacy and prognosis in non-small cell lung cancer

Efficacy and safety of osimertinib plus anlotinib in advanced non‐small‐cell lung cancer patients after drug resistance

The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study

Contact Info

Product

Resources

About